Repeated administration of DSP-5423P in patients with Schizophrenia

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222373

Enrollment

Registered

2014-01-21

Start date

2014-01-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

investigational material(s) Generic name etc : DSP-5423P INN of investigational material : Therapeutic category code : 117 Psychotropic agents Dosage and Administration for Investigational material :

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients who have a diagnosis of schizophrenia as defined by DSM-IV-TR

Exclusion criteria

Exclusion criteria: - Patients who fall under a contraindication listed in the LONASEN package insert - Patients with Parkinson disease, etc.

Design outcomes

Primary

Measure	Time frame
- Safety and Tolerability Adverse event monitoring Change in DIEPSS total score after multiple administration of DSP-5423P	—

Secondary

Measure	Time frame
- Plasma Concentration of Blonansein and its metabolites - PANSS total score and CGI-S score - Change in PANSS total score and CGI-S score after multiple administration of DSP-5423P	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026